ESR1 and breast carcinoma: The ERα antagonist MPP inhibits NRF2 activity in MCF-7 breast cancer cells, and oestrogen increases NRF2 activity in MCF7 breast cancer cells by activating the phosphoinositide 3-kinase/glycogen synthase kinase 3 beta (PI3K/GSK3β) pathway [16].